Pasithea Therapeutics Corp (NASDAQ: KTTA) — Healthcare · Share Price, Chart & Market Data
About: Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven tumors, such as BRAFv600 and BRAF fusion tumors; and ETS2 driven diseases, including inflammatory bowel disease (IBD), primary sclerosing cholangitis, and ankylosing spondylitis. The company's lead development candidate is PAS-003, to treat amyotrophic lateral sclerosis. It also intends to develop PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.
Sector: Healthcare
Industry: Biotechnology
Latest price: $0.74 (-1.33%)
KTTAPasithea Therapeutics Corp
Loading watchlist status…
Trade KTTA now
Pasithea Therapeutics Corp share price
KTTA price activity
Last Price
Change (24hr)
USD (%)
Volume
Volume (4w avg)
Previous Close
N/A
Last Trade
Delayed
17 Apr, 7:12 am GMT+0
KTTA price performance
5.143%
5D
-10.939%
1M
-38.151%
YTD
-46.277%
1Y
KTTA price fundamentals
N/A
Shares Issued
N/A
Dividends Per Share (DPS)
N/A
Earnings Per Share (EPS)
N/A
P/E Ratio
Price market cap
Market cap
N/A
NASDAQ rank
N/A
Sector Rank
N/A
Delayed
17 Apr, 7:12 am GMT+0
KTTA details
KTTA Market Signals